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Clinical Trials: II. Randomization and Sample Size
Barbara Tilley, PhD,* and Anthony Schork PhDt
This second in a series of articlest focuses on clinical trials.
Information is provided on determining sample size and on
methods of randomization including simple and single- and

double-consent randomization, and blocked, stratified, and
adaptive procedures to randomize patients to a study group.

A clinical trial is a "prospective study comparing the effect
and value of interventions against a control in human
subjects" (1). Clinical trials usually include at least two
interventions. Ideally, the members of the groups undergoing the interventions should be comparable in every way
except for the treatments they receive. Subjects should be
followed up from a well-defined starting point to a welldefined ending point. Subjects are usually randomly assigned to the different treatment groups, and a sample size
is chosen to ensure that enough patients are followed up to
reach a definitive conclusion about the efficacy of each
intervention. Additionally, clinical trials are usually performed in a blinded fashion, ie, neither the clinician
providing nor the patient receiving the treatment knows
which treatment is being used. The focus of this article is
on those aspects of clinical trials relating to randomization
and sample size.

pointed when some of these patients were not assigned to
the exercise program. If the staff had influenced assignments,
it is possible that all favorite patients would have been
assigned to the exercise program.

Randomization
The following appeared in the New England Journal of
Medicine (2): "Somewhere between 1910 and 1912 in this
country, a random patient, with a random disease, consulting a doctor chosen at random, had, for the first time in the
history of mankind, a better than fifty-fifty chance of profiting
from this encounter." This statement could be considered
a tender jibe at the process of randomization in which
statisticians place so much faith. However, randomization
fulfills an essential role in the design and consequent validity
of a clinical trial. Randomization means that the choice of
treatments for a study patient is determined by a chance or
random process.

Another advantage of randomization is in assuring that
variables (such as age, sex, and health status) are on fhe
average evenly balanced among the treatment regimens. For
example, if instead of using randomization all patients who
are most ill are given treatment A, and all remaining patients
are given treatment B, then treatment A could appear to be
less effective than treatment B, because the patients receiving treatment A were more ill at the beginning of the study.
In addition, random assignment to a treatment group
guarantees that statistical tests will have valid levels of
significance.
Randomization also has disadvantages. Some physicians are
concerned that randomization undermines the doctorpatient relationship. Randomization is less acceptable to the
patient than assignment based on individual therapeutic
consideration, and patients sometimes refuse to understand
that they are being assigned in a random manner even when
they are informed. Figure 1 shows the traditional method
of randomization. To minimize patient concerns, Zelen (3)
proposed single- and double-consent randomizations.
When the method of single-consent randomization is used,
consent is not sought if the patient is assigned to the control
group and the control group is receiving standard care.
Consent is required if the patient is randomly placed in the
treatment group (Fig 2). In analyzing the trial, patients
randomized to treatment are members of the treatment
group whether they have consented and received treatment

Randomized designs have several advantages (1). Randomization removes the potential bias in allocating subjects to
a treatment regimen. For example, when the benefit of
exercise after myocardial infarction was being studied,
patients had several clinic visits prior to random placement
in either the control or the treatment group. The staff
involved in the study strongly believed in the benefit of
exercise. Some had "favorite" patients and were disap-
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Figl
An example of traditional randomization.

Fig 2
An example of single consent randomization.

because parents are likely to give consent for the new
treatment. In the double-consent randomization, patients
are randomly assigned treatment group A or B and then
asked whether they wish to receive treatment A or B (Fig
3). Again, when doing the analysis, patients are maintained
as a part of the group to which they are randomized,
regardless of treatment assignment. The Table gives the
efficiency of these designs. If the probability of accepting
the treatment is high, as in the newborn study, then only a
small number of additional patients are required in order to
do this type of study. However, as the probability of
accepting the assigned treatment decreases, the sample-size
requirement increases. If patients have only a 6 0 % probability of accepting the treatment to which they are assigned,
25 times more patients are required to perform the trial in
the double-consent design, and 2.8 times more patients are
required in the single-consent design. Also these designs do
not allow blinding.

treatment groups. Suppose, for example, that most male
patients were randomized to treatment A by chance. If men
do not respond as quickly to treatment as women, it may
be incorrectly concluded that treatment A is inferior to
treatment B.

Randomization has another disadvantage, especially if the
total number of patients in the study is small. Randomization
provides only a balance of prognostic variables on the
average. Sometimes, by chance, unequal numbers of patients with the same prognostic variables are assigned to the

Other alternatives include numbered envelopes containing
the treatment assignments that are given to the investigators.
These envelopes must be truly opaque and well sealed.
Curious staff members have been known to hold envelopes
up to strong light to see the contents. It is also important to
record the envelope number as a part of the patient data.
Later these numbers should be checked against date of study
entry to assure that the order of treatment assignment was
maintained. Another approach used by the Beta Blocker
Heart Attack Trial (BHAT) was an automated system. Data
that defined eligibility (age, other medical conditions, blood

Table
Efficiencies of Single- and Double-Consent Randomized Design*

Probability of
Acceptance

Single Consent

Double Consent

Break Even
Accrual Factort

Break Even
Accrual Factor

0.50

4

0.60

2.8

25.0

0.70

2.0

6.2

0.80

1.6

2,8

0.90

1 .2

1.6

0.95

1.1

1.2

Finally, implementation of the actual randomization process
can be cumbersome because the allocation of treatments
should be unpredictable. The clinician should have no
knowledge of which treatment the next patient will be
randomized to receive. Once a randomization list is developed, it should not be made available to the person
performing the study. Instead, the list should be kept by
someone outside the study who will give out the treatment
assignment after receiving some patient-identifying information. In the exercise treatment example, it is easy to see that
if treatment assignments were known and two patients
became eligible on the same day, some bias could occur
in the treatment assignment.

Do you
wish A?

/

—H Yes
No

- • A

YeslDo you
wish B? —H No I-

*Zelen (3)
(The number given multiplied by the proposed sample size for the
tnai is the number of patients to be studied. For example, if the
probability of acceptance is 0.5 and the original sample size was
50 per group, 200 per group would be needed for the single
consent, and the study could not be done with a double-consent
design.

(Control)

- » - B or other (Experimental
or other
treatment)

"•B (Experimental treatment)
••A or other (Control or
other
treatment)

Fig 3
A n example of double-consent randomization.
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pressure, etc) would be provided from clinical centers to the
coordinating center and entered interactively into a computer. After checking criteria and determining that the
patient was eligible, the computer generated the treatment
assignment and recorded the assignment in the data base
for that patient.
Performing randomization
Several different methods are used to randomize patient
treatments. The easiest to apply is simple randomization,
which proceeds for all subjects without restriction. Randomly generated numbers from tables (5) or from automated
random-number generators can be used to assign patients
to treatment groups. Random numbers could also be
generated by rolling a die or dice. For the two-treatment
case, treatment assignment could also be generated by
tossing a coin. If simple randomization is to be used and two
treatments compared, the odd numbers (or heads on a coin)
could represent treatment A and the even numbers (or tails
on a coin) treatment B. Simple randomization is easy to
implement, but the groups could be unbalanced in small
studies.
Blocked randomization is used to ensure that after a specific
number of patients are entered, the same number of patients
is assigned to each treatment group. If the block size is eight,
and there are two treatments, then four of every eight
patients entered would be on treatment A and four on
treatment B, Blocked randomization has two important
advantages. If the type of subject recruited for study changes
during the entry period, blocking will produce more comparable groups, and if the trial is terminated at any time,
balance will still be achieved. There are two disadvantages.
The investigator might be able to break the code if the length
of the block is known. For example, if seven patients had
been entered in a block known to contain eight patients, and
three were assigned to treatment A and four to treatment
B, the investigator would know that the next patient would
receive treatment A. Thus, it is advisable to vary the length
of the block randomly. Also, analysis of data can be more
cumbersome if blocked randomization is used. However,
most investigators ignore the blocking and proceed with
standard analyses. By taking this approach, the true significance level is probably lowerthan computed, which means
there will be a greater chance of failing to find a difference
between treatment groups when a true difference exists (6).
Stratified randomization is used to ensure that possible
prognostic factors that might influence the outcome of
treatment are balanced among treatments (7). In this
procedure, patients are divided (stratified) into homogeneous groups (eg, by sex, age, race, or some other factor)
before randomization; then, usual randomization procedures are applied to subjects within each stratum. Note that

only important variables should be used to stratify to avoid
groups with very sparse data. It is possible to adjust for some
imbalances in prognostic variables during data analysis (8).
(Analysis will be discussed in the next article of this series.)
Stratification on area of infarct (anterior, inferior) and time
of infarct (less than three hours, three hours or more) was
used by the western Washington randomized trial for the
use of intracoronary streptokinase (9). In a multicenter
clinical trial, the clinical center is often an important factor
for stratification.
BHAT (10) and the Lipid Research Clinic study (11) used
both blocking and stratified random sampling. In BHAT,
patients were stratified only by clinical center, and block size
was randomly varied with four, six, or eight patients per

block.
Treatment allocation
Usually patients are allocated evenly among treatments. This
is called fixed allocation. For example, if there are two
treatments, A and B, 5 0 % of patients would be allocated
to treatment A, and 5 0 % to treatment B. The allocation
probabilities are not altered as the study progresses. However, for some studies, investigators may want a fixed
allocation that assigns more than 5 0 % of patients to a
particular treatment or treatments. For example, if there is
sufficient information about toxicity in the control group but
little information about toxicity on the new therapy, a
two-to-one allocation (ie, two patients randomized to
treatment for every one patient randomized as a control
subject) may be chosen (12). This allows more information
to be gathered about the new intervention.
Adaptive randomization procedures are used to change
allocation probabilities as the study progresses. Adaptive
procedures are applied when the changing probabilities
result from information about either prognostic variables
measured at entry to the study (baseline) or the response
variables.
Baseline adaptive randomization procedures include biased
coin randomization (13), which balances the number of
subjects on each regimen based on previous assignments,
and minimization randomization (14), which changes assignment probabilities as a function of the distribution of the
prognostic factors for subjects already randomized.
When biased coin randomization is used, the proportion of
patients on each treatment is calculated after a new patient
is randomized. The goal is to have equal numbers of patients
in each group. If either proportion exceeds a prespecified
amount, for example 0.6, the allocation probability is
changed from 0.5 to 0.67 to increase allocation to the group
with fewer patients.
Minimization is an extension of biased randomization. As
an example, let the prognostic variables of interest be age
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group, gender, and previous history of myocardial infarction. Suppose 20 patients have already been entered in a
trial, and the distribution between treatment and control
groups is as follows:
Gender

Age

<50

50-69

>70

Previous Ml
Never

M

is used to adjust the probabilities of allocation so that a
higher proportion of future subjects receive the currently
better intervention or treatment. To use this approach
response by treatment must be known eady in the trial.

>5
years
ago

<5
years
ago

Treatment

4

3

4

9

2

6

4

1

Control

5

3

3

10

1

7

3

1

The effect of adding a new patient to each group is assessed
by computing the sum of the absolute values of the
differences (differences without the sign) and choosing the
assignment that gives the smallest total difference. If a new
patient (age 70, male, and never had an Ml) is assigned to
treatment, the absolute value of the difference for age 70
would be 2 (5-3); for gender, 0 (10-10); and for previous
Ml, 0 (7-7).
The total difference would be 2 (2 -F-O-l-O). If the patient was
assigned as a control, the absolute value of the difference
for age would be 0 (4-4); for gender, 2 (9-11); and for
previous Ml, 2 (6-8), The total would be 4 (0-h2-1-2), Thus,
to minimize differences between groups, the new patient
would be assigned to treatment. As the number of variables
to be considered and number of study groups increase,
calculation becomes more complex. Also, some variables
may be considered more important than others, so weights
could be added. Because of this complexity, minimization
randomization is usually done by computer.
These techniques protect against a severe imbalance in
either the number of patients per treatment or in the
prognostic variables. As noted, these methods are cumbersome to implement, and minimization requires special
methods of data analysis to take this type of randomization
into account (15), If baseline adaptive procedures are used,
it is generally unnecessary to block. If prognostic variables
are used to alter patient assignment, stratification is usually
unnecessary.
Response adaptive randomization procedures use information on subject response to intervention during the course
of the trial to determine allocation of the next subject. These
include "play-the-winner" randomization (16), a process
that calls for staying with the winning intervention until a
failure occurs and then switching to the opposite intervention. An extreme example of this type of randomization was
the previously mentioned study in newborns (4), Because
the treatment was so successful, only one patient was
randomized to the control group, "Two-armed bandit"
randomization allows updating the probability of success as
soon as the outcome for each subject is known. This process

Sample Size
In addition to deciding on a randomization scheme, it is
important to consider sample size when designing a clinical
trial. According to Friedman et al (1), "clinical trials should
have sufficient statistical power to detect differences between groups considered to be of clinical interest. Calculation of sample size with provision for adequate levels of
significance and power is an essential part of planning."
Several key features in determining the size of sample
needed for a clinical trial should be considered in detail,
using as much clinical data as possible to assist in computation of number of subjects. First, investigators should
determine the most important outcome or response variable.
The distinction as to whether this variable is measured on
a discrete (usually dichotomous, eg, success/failure,
lived/died, or yes/no) or continuous scale (eg, change in
lung capacity) must be understood. Second, the investigators
should estimate the smallest difference between the interventions that they wish to detect based on the trial. In
determining this difference, the distinction between a
statistically and clinically significant difference should be
understood. It is possible to design a trial with a large sample
size to detect a small treatment difference. If only a large
treatment difference is of clinical importance, then the study
could be done at less expense with a smaller sample size.
Third, the investigators should state the hypothesis to be
tested, usually a null hypothesis implying that the response
will be the same for all interventions. The alternative
hypothesis should also be clearly stated. Does the alternative
state that the treatments are different, implying two-sided
tests, or that one treatment is better than the others, implying
a one-sided test? Fourth, the allowable alpha (probability of
rejecting the null hypothesis when it is true, or probability
of a Type I error) and beta (the probability of failing to reject
the null hypothesis when it is false, or probability of a Type
II error) should be determined. Power (the probability of
rejecting the null hypothesis when it is truly false) is one
minus beta. In clinical trials a Type I error is made if the
investigator concludes two treatments are different when,
in truth, the treatments have the same effect, A Type II error
is made when the investigator fails to find differences
between two treatments, but in truth, the treatments are
different. Frequently alpha is set at 5 % (0.05 level) and the
power at 8 0 % (beta = 20%). Because it is unlikely that
drugs from a negative trial will be retested, beta is set to 1 %
or 5 % in Phase II chemotherapy trials to avoid missing an
effective drug. Fifth, the variability of the primary outcome
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or response should be determined from the literature or from
a pilot study. If the response is a continuous measure, this
variability is usually expressed as a standard deviation or
standard error. The variability of the response can greatly
affect the sample size. In a study of chronic obstructive
pulmonary disease (COPD) (17), the variability in measurement of pulmonary function was unexpectedly extremely
large, and as a consequence, the results of the trial were
equivocal. Sample size for a new trial of the effect of smoking
cessation on pulmonary function for subjects with COPD
was estimated to be as high as 11,000 patients, based on
the variance from this previous study.
Special formulas are available to assist the investigator in
estimating requisite sample sizes per intervention group. The
choice of formula depends on the outcome to be measured.
Lachin's review article (18) gives an excellent overview of
sample size calculations for clinical trials including calculations when the outcome is a proportion or a continuous
measure. Methods have been developed (19) to take into
account the time to the outcome event (eg, time to death)
when this is important. All of the above sample size
calculations can be done using an interactive software
package (STPLAN) (20) that is available in many institutions
across the country.
Schork and Remington (21) have developed formulas for
computing sample size when drop-outs (patients who refuse
to participate in the study) are expected to be a problem,
as often happens in studies with long periods of follow-up.
In BHAT (10), both drop-outs and drop-ins were a concern.
Before the beginning of the trial, propranolol was becoming
popular as a treatment after a new myocardial infarction,
even though it had not been approved for this use in the
United States. Thus, study investigators expected some
patients who were randomized to the control group to
become drop-ins when their private physicians put them on
propranolol. In calculating sample size, the methods of
Halperin et al (22) were adapted to take into account both
drops-outs and drop-ins.

being studied but where it is also necessary to adjust the
groups for possible differences in prognostic factors. Methods (24) are also available for calculating sample size when
the comparison is a historical control group. However,
before using historical controls, the disadvantages of this
type of comparison group should be considered (25).
Often trials are planned with no knowledge of the variability
in the outcome measures or of patient acceptance of the new
treatment (ie, the possible drop-out rate). In this situation,
a carefully planned pilot study on a small number of patients
may allow the investigator to plan a clinical trial more
effectively.
Calculation of sample size and power is also essential to an
ethical trial. If the study is intended to be a clinical trial but
too few patients are studied to allow investigators to draw
conclusions, then patients may have been needlessly subjected to an experiment. A dramatic example is the smoking
cessation study. An investigator who planned to study the
effect of smoking cessation on COPD with a sample size of
200 or even 300 per group could not come to any
conclusion because of the variability in the outcome
measure. An investigator who determines that the available
sample size for a planned trial is too small has several
alternatives including abandoning the study, increasing the
recruitment period, or trying to interest other institutions in
a cooperative trial, which was done with the COPD study.
At the other extreme, if the sample size is too large, more
patients than necessary will receive the inferior treatment.
Because of the concern that patients or animals may be
subjected to unnecessary treatment in clinical trials when
the data base is too large or too small, most human-subject
and animal-care review committees consider sample size
and power to be an ethical as well as a scientific issue.
Giammona and Glantz (26) provide an excellent discussion
of the role of such committees in evaluating the statistical
design of research.

Recently, Schoenfeld (23) developed sample size calculations for a study where time to event for two treatments is
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